Evidence map›Paper›PMID 24960601›Full record

ReviewNature reviews. Urology2014

Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.

Woonyoung Choi, Bogdan Czerniak, Andrea Ochoa, Xiaoping Su, Arlene Siefker-Radtke, Colin Dinney, David J McConkey

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03577132 (The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer According to the BASQ Classification), which is not on this map. Cited by 166 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
166citing papers in PubMed, 5 pooled it
24.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03577132 naunknown statusnot on this mapstarted 2018, after this paper: background citation

The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer According to the BASQ Classification

TypeinterventionalSponsorSeoul National University HospitalRan2018 to 2022Enrolled20ConditionsUrothelial CarcinomaArmsNeoadjuvant atezolizumab
3 · Its place in the literature

Who cites it

166 citing papers in PubMed, 5 syntheses or guidelines pooled it, 309 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

106 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Woonyoung ChoiDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Bogdan CzerniakDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Andrea OchoaDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Xiaoping SuDepartment of Bioinformatics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Arlene Siefker-RadtkeDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Colin DinneyDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
David J McConkeyDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
6 · The paper itself

Abstract

Whole-genome analyses have revealed that muscle-invasive bladder cancers (MIBCs) are heterogeneous and can be grouped into basal and luminal subtypes that are highly reminiscent of those found in breast cancer. Basal MIBCs are enriched with squamous and sarcomatoid features and are associated with advanced stage and metastatic disease at presentation. Like basal breast cancers, basal bladder tumours contain a claudin-low subtype that is enriched with biomarkers characteristic of epithelial-to-mesenchymal transition. The stem cell transcription factor ΔNp63α controls basal MIBC gene expression, just as it does in basal breast cancers. Luminal MIBCs are enriched with activating FGFR3 and ERBB3 mutations and ERBB2 amplifications, and their gene expression profiles are controlled by peroxisome proliferator activator receptor γ (PPARγ) and possibly also by oestrogen receptor activation. Luminal bladder cancers can be further subdivided into two subtypes, p53-like and luminal, which can be distinguished from one another by different levels of biomarkers that are characteristic of stromal infiltration, cell cycle progression, and proliferation. Importantly, basal bladder cancers are intrinsically aggressive, but are highly sensitive to cisplatin-based combination chemotherapy. Although the luminal subtypes are not as intrinsically aggressive as basal cancers, p53-like tumours are resistant to chemotherapy and might, therefore, represent a problem for treated patients.

Indexed as

Basal Cell CarcinomaBiomarkers, TumorCarcinoma, Squamous CellErb-b2 Receptor Tyrosine KinasesGene Expression RegulationHumansMuscle NeoplasmsMutationNeoplasm InvasivenessNeoplasm StagingPPAR gammaReceptor, ErbB-3Receptor, Fibroblast Growth Factor, Type 3Tumor Suppressor ProteinsUrinary Bladder NeoplasmsBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesERBB3 protein, humanFGFR3 protein, humanPPAR gammaReceptor, ErbB-3Receptor, Fibroblast Growth Factor, Type 3Tumor Suppressor Proteins

Identifiers

PMID24960601
OpenAlexW1980808101

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.